Medipharm Labs Corp T.LABS

General Sentiment

[QContinuum1]

I think the general belief is that Pidduck (and Hunter) have done a great if not phenomenal job in getting the business this far.  I would agree that he's tops or on Mount Rushmore as far as cannabis CEOs go and we're lucky to have him.  That said, he really now needs to make good on growing the business organically and stop with this micro-biz pity projects he seems to have a fascination with.  Was Vivo a good play, yes, so no harm there, but growth is required and not just incremental.

I think more than anything, the restless natives need communication and that has been truly piss poor from the business over a long time.  The rescheduling and impact on drobinol is a new thing that I wasn't aware of so if that is true, then rescheduling is much more important than I first thought.

Nevertheless, this company has never not had lots of irons in the fire, but given the silence, it appears as if those irons are never reaching glowing status and that really is on them to make good on.  If something went sideways, let us know and tell us the recovery plan, if things are on track, say as much and give proper guidance and timelines for a change.  Basically, transition from rookie micro-cap startup to big boy pant wearing business types.

Pidduck, please issue a NR soon with some kind of update.  We need to hear something. 

[subaru1]

Well said QC

[CADInvestor12]

I think the micro biz play (Remidose) is him showing restraint/ discipline in deploying resources .. it's a low risk/ high upside move for MPL to determine what the upside is/ how quickly they can capitalize .. if it turns into a significant opp, then I would expect them to aggressively deploy resources to support.. while refreshing to see a disciplined approach by management (esp amongst

[QContinuum1]

What Remidose shows is that they're spending resources (time and likely G&A monies on consultants) looking for near dead fish that we don't need.  And in assessing those dead fish, we are wasting time and not focusing on the things that should be focused on. The walking dead will still be there when we are actually ready and if they're not, they're not.  I don't

[CADInvestor12]

Appreciate the colour & discussion - think that we are looking at it through different lenses.  I'd argue that Remidose is no where close to being classified as carcass hunting, they might not have significant IP (TBD) but it's a low risk way to expand product portfolio & one step closer to pharma-type / pharma products. While it failed a clinical trial a few years ago (MS

[QContinuum1]

Agreed it's not a big deal, but it's not the revenue impact, it's the time.  I don't need or want the leadership team worrying about or spending needless monies on lawyers drafting agreements or consultants finding carasses.  They need to be laser focused on growing the top line with what they have and finding partners to make that happen if the partners they currently

[Starkicker]

Germany, like Canada, has tight restrictions on the advertising/sponsorship of cannabis products. There is essentially no marketing, advertising, or sponsorships allowed.

[QContinuum1]

Good to know, but marketing in Germany was but one example.  If not stuff like that, then hosting channel events, hiring robo-callers to talk to each and every Apotheke in the Buende, whatever.  They need to find a way to become a prime mover in Germany and have money to support that.